EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing

Émilie Audrey Larose, Xinying Hua, Silin Yu, Amritha Thulaseedharan Pillai, Zongbi Yi, Haijun Yu

Cancer Drug Resistance · 06.03.2025

DOI: 10.20517/cdr.2024.180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 06.03.2025. Verfasst von Émilie Audrey Larose und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospit…. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are a transformative approach in breast cancer therapy, offering targeted treatment with reduced toxicity by selectively delivering cytotoxic agents to cancer cells. While ADCs like trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and sacituzumab govitecan have shown significant efficacy, resistance mechanisms such as antigen loss, impaired internalization, and efflux of cytotoxic payloads challenge their effectiveness. This review discusses these resistance mechanisms and explores advanced strategies to overcome them, including innovations in linker chemistry, multi-antigen targeting, and biomarker-driven personalization. Additionally, therapeutic sequencing - determining the optimal order of ADCs with other treatments such as chemotherapy, endocrine therapy, and immunotherapy - is examined as a crucial approach to maximize ADC efficacy and manage resistance. Evidence-based sequencing strategies, particularly for human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC), are supported by clinical trials demonstrating the benefits of ADCs in both early-stage and metastatic settings. The potential of combination therapies, such as ADCs with immune checkpoint inhibitors (ICIs), further highlights the evolving landscape of breast cancer treatment. As ADC technology advances, personalized approaches integrating biomarkers and optimized sequencing protocols offer promising avenues to enhance treatment outcomes and combat resistance in breast cancer.

Schlagwörter

Stichwörter der Autor:innen

Antibody-drug conjugatesbreast cancercombination therapyresistance mechanismstargeted treatmenttherapeutic sequencing

Autor:innen und Institutionen

  • Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, China.
  • Authors contributed equally.
  • Wuhan Britain-China School, Wuhan 430071, Hubei, China.
  • School of Medicine, Wuhan University, Wuhan 430071, Hubei, China.

Zitieren

APA

Larose, É. A., Hua, X., Yu, S., Pillai, A. T., Yi, Z., & Yu, H. (2025). Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2024.180

Vancouver

Larose ÉA, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resistance. 2025. doi:10.20517/cdr.2024.180

BibTeX
@article{Larose2025,
  author = {Larose, Émilie Audrey and Hua, Xinying and Yu, Silin and Pillai, Amritha Thulaseedharan and Yi, Zongbi and Yu, Haijun},
  title = {Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing},
  journal = {Cancer Drug Resistance},
  year = {2025},
  doi = {10.20517/cdr.2024.180}
}
Kostenlos starten →